Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
A Phase 1 Study of Menin-KMT2A Inhibitor Ziftomenib (KO-539) in Combination With Cereblon E3 Ligase Modulator Mezigdomide (CC-92480) in Adolescents and Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with ei…
KMT2A-rearrangedNPM1-mutant Refractory or Relapsed AML
Massachusetts General HospitalNCT07355335
Phase 1
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
To learn about the safety and effects of revumenib in combination with blinatumomab in patients with newly diagnosed or relapsed/refractory Ph-negative ALL wit…
BlinatumomabRevumenibLymphoblastic Leukemia+1 more
M.D. Anderson Cancer CenterNCT07283640